Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great ...

By 2030, we won't be asking AI what the data says. I believe we'll be asking it what we should create next. The creative ...

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...